Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]

Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]

Anónimo. FDA Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax) . U.S. Food and Drug Administration 2016:10 de mayo. [Ref.ID 100267]

Anónimo. Ziprasidone (marketed as Geodon and generics): Drug Safety Communication - Rare but potentially fatal skin reactions. U.S. Food and Drug Administration 2014:11 de diciembre. [Ref.ID 98379]

Anónimo. Régorafénib: hypersensibilités multiorganiques. Prescrire 2014;34:749. [Ref.ID 98265]

Anónimo. Vemurafenib: DRESS syndrome. Singapore. WHO Drug Information 2013;27:222-3. [Ref.ID 96293]